Reassortant Or Deletion Mutant Virus Patents (Class 424/205.1)
-
Patent number: 8202521Abstract: The present invention provides methods and compositions for modulating an immune response in a subject, comprising administering to the subject an effective amount of an A35R protein or active fragment thereof of vaccinia virus or other poxvirus.Type: GrantFiled: March 1, 2006Date of Patent: June 19, 2012Assignee: East Carolina UniversityInventor: Rachel Roper
-
Patent number: 8173136Abstract: The present invention relates to a recombinant vector for transcription of the Newcastle disease virus (NDV) genome, a strain of attenuated recombinant NDV with a surface antigen of pathogenic NDV prepared by the vector, a method of preparing a recombinant NDV having low pathogenicity and high protectivity efficiency against Newcastle disease (ND) using the vector, and a vaccine against ND containing the recombinant NDV.Type: GrantFiled: September 27, 2006Date of Patent: May 8, 2012Assignees: KBNP, Inc., Biopoa, Inc.Inventors: Sun-Hee Cho, Hyuk-Joon Kwon, Sun-Joong Kim, Tae-Eun Kim, Young-Jin An, Mi-Joung Ko, Il-Hwan Kim, Young-Ho Park, Chae-Hyun Kim, Jang-Hyuck Han, Tae-Hwan Kim
-
Patent number: 8173137Abstract: The present disclosure relates to vectors comprising polynucleotide sequences that encode HIV polypeptides. In particular, the disclosure relates polycistronic vector constructs comprising sequences that encode HIV polypeptides as a single polyprotein. Compositions comprising these vectors and sequences along with methods of using these vectors and sequences are also disclosed.Type: GrantFiled: October 22, 2009Date of Patent: May 8, 2012Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Jan Zur Megede, Susan W. Barnett
-
Patent number: 8168202Abstract: The present invention provides vaccine compositions for protection against human rotaviral disease designed for use in particular areas of the world. Human× bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined with other VP7 serotypes typically found in the area of interest into a multivalent formulation which provides a high degree of infectivity and immunogenicity. Methods and an administration protocol for producing an immunogenic response without producing an increased risk of intussusception are also provided.Type: GrantFiled: July 7, 2006Date of Patent: May 1, 2012Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Albert Z. Kapikian, Lone Simonsen, Timo Vesikari, Yasutaka Hoshino, David M. Morens, Robert M. Chanock, John R. La Montagne, Mary Elaine La Montagne, legal representative, Brian R. Murphy
-
Publication number: 20120076820Abstract: The disclosure relates to vaccinating a subject against a viral infection, compositions, and methods related thereto. In certain embodiments, the disclosure relates to the use of CD40L expressed on viral like particle as an adjuvant, in combination with a viral antigen, to vaccinate a subject.Type: ApplicationFiled: September 28, 2011Publication date: March 29, 2012Applicant: EMORY UNIVERSITYInventors: Rama Rao Amara, Lilin Lai, Sue Fen Kwa
-
Publication number: 20120076821Abstract: Disclosed herein are chimeric TBEV/DEN4 flaviviruses including a first nucleic acid molecule including a 5? non-coding region (NCR) from a DEN4 virus, a nucleic acid encoding a C protein and non-structural proteins from a DEN4 virus, and a 3? NCR from a DEN4 virus, wherein nonstructural protein NS4B includes a phenylalanine at amino acid position 112, nonstructural protein NS5 includes an alanine at amino acid position 654 and an alanine at amino acid position 655, and the 3? NCR includes a deletion of nucleotides 10478-10507. The chimeric construct also includes a second nucleic acid molecule, which is operably linked to the first nucleic acid molecule, encoding a prM protein and an E protein from a TBEV, wherein the E protein includes an amino acid substitution that differs from the wild type TBEV at amino acid position 315 and a tryptophan at amino acid position 240.Type: ApplicationFiled: May 28, 2010Publication date: March 29, 2012Inventors: Alexander G. Pletnev, Brian R. Murphy, Amber R. Engel
-
Patent number: 8114415Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. A method of producing a cold adapted (ca) influenza virus that replicates efficiently at, e.g., 25° C. (and immunogenic compositions comprising the same) is also provided.Type: GrantFiled: October 20, 2008Date of Patent: February 14, 2012Assignee: Medimmune, LLCInventors: Erich Hoffmann, Hong Jin, Bin Lu, Gregory Duke, George Kemble, Zhongying Chen
-
Patent number: 8080255Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.Type: GrantFiled: October 18, 2006Date of Patent: December 20, 2011Assignee: Novavax Inc.Inventors: Gale Smith, Rick Bright, Peter Pushko, Jinyou Zhang, Kutub Mahmood
-
Patent number: 8075903Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.Type: GrantFiled: March 4, 2009Date of Patent: December 13, 2011Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley
-
Patent number: 8067012Abstract: Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the ?34.5 gene in the long repeat region (RL) such that the ?34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.Type: GrantFiled: January 22, 2010Date of Patent: November 29, 2011Assignees: Crusade Laboratories Limited, The Wistar InstituteInventors: Alasdair Roderick MacLean, Susanne Moira Brown, Nigel William Fraser, Bruce Paul Randazzo
-
Publication number: 20110280904Abstract: In this application are described filovirus-like particles for both Ebola and Marburg and their use as a diagnostic and therapeutic agent as well as a filovirus vaccine. Also described is the association of Ebola and Marburs with lipid rafts during assembly and budding, and the requirement of functional rafts for entry of filoviruses into cells.Type: ApplicationFiled: February 18, 2011Publication date: November 17, 2011Inventors: Sina Bavari, Kelly L. Warfield, Warren Kalina
-
Publication number: 20110268762Abstract: The present invention relates generally to the fields of immunology and vaccine technology. More specifically, the invention relates to mucosal administration via aerosol spray to avians of immunogenic and vaccine compositions, including those comprising recombinant human adenovirus vectors for delivery of genes encoding avian immunogens or antigens, such as genes encoding avian influenza virus. The invention also provides methods and apparatus for use in such administration.Type: ApplicationFiled: March 25, 2011Publication date: November 3, 2011Inventors: Haroldo Toro, De-Chu C. Tang, Kent R. Van Kampen
-
Patent number: 8048427Abstract: The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection.Type: GrantFiled: February 27, 2009Date of Patent: November 1, 2011Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Xiaowu Pang, Andrew I. Dayton, Mingjie Zhang
-
Patent number: 8039002Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: August 9, 2007Date of Patent: October 18, 2011Assignee: Medimmune, LLCInventors: Chin-Fen Yang, George Kemble
-
Patent number: 7981429Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: March 6, 2009Date of Patent: July 19, 2011Assignee: Medimmune, LLCInventors: Chin-Fen Yang, George Kemble
-
Publication number: 20110171256Abstract: The present invention relates to viral strains derived from the vaccinia virus Lister VACV-107 and to pharmaceutical composition containing the viral strains. More particularly, the present invention relates to a viral strain derived from the vaccinia virus Lister VACV-107 wherein strain contains in its genomic sequence (SEQ ID N°1) at least one deletion selected from the group consisting of: deletion of the nucleotides 19758 to 28309 in the sequence ID NO°1 (?18), deletion of the nucleotides 161293 to 164811 in the sequence ID NO°1 (?20), deletion of the nucleotides 181231 to 183304 in the sequence ID NO°1 (?21), deletion of the nucleotides 6118 to 9677 in the sequence ID NO°1 (?22), deletion of the nucleotides 1833 to 3574 and 185848 to 187589 in the sequence ID NO°1 (?23).Type: ApplicationFiled: September 18, 2009Publication date: July 14, 2011Inventors: Jean-marc Crance, Daniel Garin, Daniele Gratier, Anne-Laure Favier, Robert Drillien, Matthias Hebben, Daniele Spehner, Karine Pradeau
-
Publication number: 20110165230Abstract: Disclosed is an attenuated flavivirus live vaccine comprising a flavivirus mutant, characterised in that the flavivirus mutant has a deletion in the capsid protein of at least more than 4 successive amino acids, wherein the carboxy-terminal hydrophobic region is not affected by the deletion.Type: ApplicationFiled: March 15, 2011Publication date: July 7, 2011Inventors: Franz Xaver HEINZ, Christian MANDL
-
Publication number: 20110165189Abstract: Described herein are recombinant rabies viruses comprising a heterologous nucleic acid sequence encoding an immunocontraceptive protein, such as gonadotropin-releasing hormone (GnRH) or zona pellucida 3 (ZP3). The recombinant rabies viruses disclosed herein are recovered by reverse genetics, replicate efficiently, elicit rabies virus neutralizing antibodies and immunocontraceptive peptide-specific antibodies in vaccinated animals, and protect vaccinated animals against wild-type rabies virus challenge. Further provided is a method of immunizing a non-human animal against rabies virus infection and simultaneously inhibiting fertility of the animal, comprising administering an immunogenic composition comprising one or more of the recombinant rabies viruses described herein.Type: ApplicationFiled: August 20, 2009Publication date: July 7, 2011Inventors: Xianfu Wu, Charles Rupprecht
-
Publication number: 20110159034Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition.Type: ApplicationFiled: November 5, 2010Publication date: June 30, 2011Inventors: Andrew McMICHAEL, Adrian V.S. Hill, Sarah C. Gilbert, Jörg Schneider, Magdalena Plebanski, Tomas Hanke, Geoffrey L. Smith, Tom Blanchard
-
Publication number: 20110159036Abstract: The invention provides modified virus Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.Type: ApplicationFiled: October 19, 2007Publication date: June 30, 2011Inventors: Bernard Moss, Patricia L. Earl, Linda Wyatt, Leigh Anne Eller, Thomas C. VanCott, Matthew Edward Harris
-
Publication number: 20110159032Abstract: The invention relates inter alia to a method for inducing a long-term protection in an animal against foreign antigens and tumor antigens comprising the step of administering to the animal at least one factor selected from type I interferons and Flt-3, and to a method for inducing a long-term increase of the number of dendritic cells in an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3 and to a method of inducing or enhancing the maturation and/or for the activation of the immune system of an animal comprising the step of administering to the animal a factor selected from type I interferon and Flt-3.Type: ApplicationFiled: January 14, 2011Publication date: June 30, 2011Applicant: BAVARIAN NORDIC A/SInventors: Mark Suter, Sabine Vollstedt, Paul Chaplin
-
Patent number: 7968101Abstract: The invention provides a composition useful to prepare influenza viruses, e.g., in the absence of helper virus, using vectors which include tandem transcription cassettes containing PolI and/or PolII promoters.Type: GrantFiled: November 18, 2005Date of Patent: June 28, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Yoshihiro Kawaoka, Gabriele Neumann
-
Publication number: 20110142912Abstract: The present invention relates to the use of a lipid vesicle for the preparation of a medicament. The invention further relates to a method of treating and/or preventing a disease or disorder involving administering such a lipid vesicle to an animal in need thereof.Type: ApplicationFiled: December 31, 2007Publication date: June 16, 2011Inventors: Christian Moser, Andreas Kammer, Rinaldo Zurbriggen
-
Publication number: 20110142877Abstract: The present invention relates to the rapid induction of a protective immune response against infectious agents using a poxvirus. An immune response can be induced by administering the poxvirus 7 to 2 days prior to infection with the infections agents.Type: ApplicationFiled: August 23, 2007Publication date: June 16, 2011Inventors: Paul Chaplin, Luis Mateo
-
Patent number: 7959929Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.Type: GrantFiled: October 19, 2006Date of Patent: June 14, 2011Assignees: University of Florida Research Foundation, Inc., Cornell Research Foundation, Inc., The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention, Intervet International B.V.Inventors: Patti C. Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, Nancy J. Cox, William L. Castleman
-
Publication number: 20110123567Abstract: Described herein are recombinant RVF viruses comprising deletions in one or more viral virulence genes, such as NSs and NSm. The recombinant RVF viruses, generated using a plasmid-based reverse genetics system, can be used as vaccines to prevent infection of RVF virus in livestock and humans. As described herein, the recombinant RVF viruses grow to high titers, provide protective immunity following a single injection and allow for the differentiation between vaccinated animals and animals infected with wild-type RVF virus.Type: ApplicationFiled: December 16, 2008Publication date: May 26, 2011Applicants: HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTIONInventors: Brian H. Bird, Cesar G. Albarino, Stuart T. Nichol, Thomas G. Ksiazek
-
Publication number: 20110117126Abstract: The present invention relates to recombinant attenuated pestiviruses, in particular to recombinant attenuated CSFV, BVDV, or BDV, wherein said recombinant attenuated pestivirus does not produce a dimeric Ems glycoprotein. The present invention also relates to immunogenic compositions comprising such a pestivirus as well to a method of attenuating a pestivirus comprising the step of modifying the Ems glycoprotein by a deletion, insertion or substitution wherein such modification results in a non dimeric Ems glycoprotein.Type: ApplicationFiled: June 24, 2009Publication date: May 19, 2011Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventors: Gregor Meyers, Birke Andrea Tews, Eva-Maria Schuermann
-
Patent number: 7932074Abstract: The present invention provides vaccine compositions for protection against human rotaviral disease without significant reactogenicity. Human×bovine reassortant rotavirus comprising each of the four clinically most important VP7 serotypes of human rotavirus are combined in a multivalent formulation which provides a high degree of infectivity and immunogenicity without producing a transient febrile condition. Methods for producing an immunogenic response without producing a transient febrile condition are also provided.Type: GrantFiled: July 27, 1999Date of Patent: April 26, 2011Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Albert Z. Kapikian, Robert M. Chanock, Yasutaka Hoshino
-
Publication number: 20110086064Abstract: Screening and diagnostic reagents, kits and methods for metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing metastatic colorectal cancer or primary and/or metastatic stomach or esophageal cancer are disclosed.Type: ApplicationFiled: August 20, 2010Publication date: April 14, 2011Inventors: Scott A. Waldman, Jason Park, Stephanie Schulz
-
Publication number: 20110070262Abstract: The invention provides viral vectors (e.g., herpes viral vectors) and methods of using these vectors to treat disease.Type: ApplicationFiled: March 11, 2010Publication date: March 24, 2011Inventors: Paul Johnson, Robert L. Martuza, Samuel D. Rabkin, Tomoki Todo
-
Publication number: 20110052630Abstract: Provided herein are methods and compositions for use in treating HSV-related conditions and diseases.Type: ApplicationFiled: July 15, 2010Publication date: March 3, 2011Inventors: Bin He, Dustin Verpooten, Yijie Ma
-
Patent number: 7897146Abstract: The use of Herpes Simplex Virus (HSV) in the treatment of tumour by extratumoural administration of HSV, and the use of HSV in treatment of tumour by combination therapy with a pharmaceutical wherein the HSV and/or pharmaceutical is administered at an extratumoural location, is disclosed.Type: GrantFiled: August 30, 2006Date of Patent: March 1, 2011Assignee: Crusade Laboratories LimitedInventors: Susanne Moira Brown, Guy Michael Gary Hamilton
-
Publication number: 20110045020Abstract: This invention provides infectious chimeric HCV particles that can be used for vaccines. This invention further provides a nucleic acid comprising a chimeric gene derived from the hepatitis C virus comprising regions each encoding Core protein, E1 protein, E2 protein and p7 protein derived from a hepatitis C virus strain other than JFH-1 strain; NS2 protein derived from JFH-1 strain or a hepatitis C virus strain other than JFH-1 strain, or a chimeric NS2 protein of NS2 protein derived from JFH-1 strain and NS2 protein derived from a hepatitis C virus strain other than JFH-1 strain; and NS3 protein, NS4A protein, NS4B protein, NS5A protein, and NS5B protein derived from JFH-1 strain in that order in 5? to 3? direction, wherein the 328th proline residue from the amino acid residue at N-terminus of the Core protein is substituted with an amino acid residue other than proline. This invention further provides chimeric HCV particles comprising such nucleic acid, and use of such HCV particles for vaccines.Type: ApplicationFiled: April 24, 2009Publication date: February 24, 2011Inventors: Daisuke Akazawa, Takaji Wakita
-
Publication number: 20110027313Abstract: The invention uses recombinant technology to create infectious molecular clones that capture the sequence diversity of viral genes found in natural populations of mixed genotype viruses, such as arises during HIV infections and many other viral diseases. The invention captures the sequence diversity of different genes in these “quasi-species” populations by recombining them into in a constant genetic “backbone” for each viral species by backcrossing PCR products derived from quasispecies gene variants into this backbone in an E. coli BAC plasmid.Type: ApplicationFiled: April 6, 2009Publication date: February 3, 2011Applicant: University Of MiamiInventors: Rebeca Geffin, Richard Myers
-
Patent number: 7871626Abstract: The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by altering receptor specificity and/or antibody-antigen binding. HA molecules containing such substitutions will be useful in the development of diagnostic reference viruses and improved influenza vaccines.Type: GrantFiled: July 27, 2006Date of Patent: January 18, 2011Assignee: St. Jude Children's Research HospitalInventors: Erich Hoffmann, Aleksandr S. Lipatov, Richard J. Webby, Elena A. Govorkova, Robert G. Webster
-
Publication number: 20110008282Abstract: Immunization of a mammal with IL-1?, which causes the mammal to generate IL-1? autoantibodies, can be used to reduce the risk and severity of, or to reduce progression of, an atherosclerosis-related disease in the mammal. Progression of atherosclerosis-related diseases such as peripheral ischemic heart disease, coronary artery disease, cerebrovascular disease, and peripheral arterial disease can be reduced using this treatment.Type: ApplicationFiled: September 22, 2010Publication date: January 13, 2011Applicant: XBIOTECH, INC.Inventor: John Simard
-
Patent number: 7862829Abstract: The present invention provides viral adjuvants for enhancing an immune response to an immunogen. In particular embodiments, the viral adjuvant is an alphavirus adjuvant or a Venezuelan Equine Encephalitis viral adjuvant. Also provided are compositions comprising the viral adjuvant and an immunogen, and pharmaceutical formulations comprising the viral adjuvant or compositions of the invention in a pharmaceutically acceptable carrier. Further provided are methods of producing an immune response against an immunogen in a subject comprising administering the immunogen and a viral adjuvant of the invention to the subject.Type: GrantFiled: July 8, 2005Date of Patent: January 4, 2011Assignee: University of North Carolina at Chapel HillInventors: Robert E. Johnston, Joseph M. Thompson
-
Patent number: 7858099Abstract: This invention relates to attenuated pestiviruses characterised in that their enzymatic activity residing in glycoprotein ERNS is inactivated, methods of preparing, using and detecting these.Type: GrantFiled: August 20, 2007Date of Patent: December 28, 2010Assignee: Boehringer Ingelheim Vetmedica GmbHInventor: Gregor Meyers
-
Publication number: 20100323003Abstract: The present invention relates to a mutant virus of the family flaviviridae, comprising a deletion in the capsid protein of at least 20 successive amino acids, without any further deletion, substitution or insertion mutation except of the amino acids next to the deletion, which may be substituted.Type: ApplicationFiled: February 6, 2009Publication date: December 23, 2010Applicant: INTERCELL AGInventors: Franz X. Heinz, Christian Mandl, Petra Schlick, Andreas Meinke
-
Publication number: 20100310601Abstract: The present invention provides adeno-associated virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV) genomes, methods for packaging rAAV genomes, stable host cell lines producing rAAV and methods for delivering genes of interest to cells utilizing the rAAV. Particularly disclosed are rAAV useful in generating immunity to human immunodeficiency virus-1 and in therapeutic gene delivery for treatment of neurological disorders.Type: ApplicationFiled: January 19, 2010Publication date: December 9, 2010Applicant: NATIONWIDE CHILDREN'S HOSPITAL INC.Inventor: Philip R. Johnson
-
Patent number: 7846454Abstract: The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.Type: GrantFiled: April 9, 2007Date of Patent: December 7, 2010Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Masayuki Yanagi, Jens Bukh, Suzanne U. Emerson, Robert H. Purcell
-
Publication number: 20100291142Abstract: The present invention relates to recombinant feline herpes virus type 1 (FHV-1) nucleic acids and proteins. In particular the present invention provides compositions comprising the full length FHV-1 genome or portions thereof, and infectious FHV-1 virions produced therefrom. The FHV-1 compositions are suitable for use in inducing an immune response in inoculated subjects and for use in identifying agents that attenuate FHV-1 infection.Type: ApplicationFiled: October 17, 2008Publication date: November 18, 2010Inventors: Roger Maes, Tai Shih-Han, Niikura Masahiro, Cheng Hans, Kruger John
-
Patent number: 7824690Abstract: An effective vaccine for Marek's disease may be prepared using a viral agent which is a Marek's disease virus unable to express a functional meq protein. This viral agent is effective to elicit an immune response in a chicken to very virulent strains of Marek's disease virus without causing a significant degree of pathogenicity in the inoculated bird. Suitable formulations of the vaccine for use in chickens include an effective immunization dosage of this novel viral agent with a pharmaceutically acceptable carrier or diluent.Type: GrantFiled: May 4, 2007Date of Patent: November 2, 2010Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Sanjay M. Reddy, Blanca M. Lupiani
-
Patent number: 7811582Abstract: An attenuated herpes virus which lacks a functional vhs gene or a functional equivalent thereof, but which has a functional UL43 gene or functional equivalent thereof, stimulates an immune response when dendritic cells are infected with the virus.Type: GrantFiled: January 18, 2006Date of Patent: October 12, 2010Assignee: Biovex LimitedInventor: Robert S. Coffin
-
Publication number: 20100233204Abstract: The present disclosure relates to multivalent immunogen compositions for treating or preventing diseases or disorders in canines caused by or associated with one or more of canine distemper virus, canine adenovirus (type 1 or type 2), canine parainfluenza virus, canine parvovirus, Leptospira canicola, Leptospira icterohaemorrhagiae, Leptospira grippotyphosa, Leptospira pomona, Leptospira bratislava, Leptospira hardjo, Leptospira autumnalis, Leptospira australis, Leptospira hebdomadis, and Bordetella bronchiseptica. The Leptospira compositions can also be used for treating or preventing leptospirosis diseases or disorders in canine, swine, and bovine.Type: ApplicationFiled: February 25, 2008Publication date: September 16, 2010Applicant: WYETHInventor: Michael Alonzo Gill
-
Patent number: 7790181Abstract: Live attenuated Eastern Equine Encephalitis (EEE) vaccines that outperform the PE-6 vaccine in mice aerosol challenged with >1,000×LD50. Candidates include four furin-cleavage deletion mutants and one E3 deletion mutant. Each vaccine provided protection in birds against antigenically distinct North and South American strains of EEE. The PE-6 vaccine does not provide protection against South American EEEs. Animals inoculated with each of the vaccines of the invention developed neutralizing antibodies to EEE.Type: GrantFiled: May 26, 2004Date of Patent: September 7, 2010Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Peter L. Platteborze, Michael D. Parker
-
Publication number: 20100215694Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, wherein the polynucleotide molecule lacks at least one detectable antigenic epitope of North American PRRS virus. The invention also provides vaccines comprising genetically modified North American PRRS virus, RNA molecules, plasmids and viral vectors comprising the isolated polynucleotide molecules. Also provided are isolated polynucleotide molecules further comprising at least one nucleotide sequence that encodes a detectable heterologous antigenic epitope, and vaccines comprising North American PRRS virus, RNA molecules, plasmids and viral vectors comprising such isolated polynucleotide molecules.Type: ApplicationFiled: October 29, 2009Publication date: August 26, 2010Inventors: JAY GREGORY CALVERT, MICHAEL G. SHEPPARD, SIAO-KUN W. WELCH, RAYMOND R.R. ROWLAND, DAL-YOUNG KIM
-
Publication number: 20100215692Abstract: The invention relates to Dengue chimeric viruses which are less prone to accumulate point mutations and genetic variations. In these Dengue chimeric viruses, the NS5 gene, which encodes polymerase, has been replaced by the corresponding NS5 sequence of a Yellow Fever virus.Type: ApplicationFiled: January 4, 2007Publication date: August 26, 2010Applicant: SANOFI PASTEUR SAInventor: Marie-Jose QUENTIN-MILLET
-
Publication number: 20100209454Abstract: This invention provides an attenuated virus which comprises a modified viral genome containing nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce synonymous deoptimized codons into the genome. The instant attenuated virus may be used in a vaccine composition for inducing a protective immune response in a subject. The invention also provides a method of synthesizing the instant attenuated virus. Further, this invention further provides a method for preventing a subject from becoming afflicted with a virus-associated disease comprising administering to the subject a prophylactically effective dose of a vaccine composition comprising the instant attenuated virus.Type: ApplicationFiled: March 31, 2008Publication date: August 19, 2010Inventors: Eckard Wimmer, Steve Skiena, Steffen Mueller, Bruce Futcher, Dimitris Papamichail, John Robert Coleman, Jeronimo Cello
-
Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
Patent number: 7771979Abstract: Methods are provided for generating immune responses utilizing alphavirus-based vector systems.Type: GrantFiled: February 27, 2007Date of Patent: August 10, 2010Assignee: Novartis Vaccines & Diagnostics, Inc.Inventors: John Polo, Thomas W. Dubensky, Jr., Ilya Frolov, Jason P. Gardner, Gillis Otten, Susan Barnett, David A. Driver